Recorded on 06/30/23

Over the last decade, contract research organizations (CROs) have become an increasingly important stakeholder in the clinical trial process. Over half of biopharma R&D budgets are outsourced to CROs, up from less than one-third ten years ago. With the high costs of drug development and importance of time to approval, CROs are relied upon for trial expertise, site networks, and abilities to accelerate KPIs such as study start up and recruitment timelines. Following a period of heightened biopharma funding during the pandemic that fueled demand for CRO services, we now enter a period of uncertainty as to where R&D budgets go from here and whether CROs can innovate their people-intensive processes to improve drug development costs and timelines going forward. To discuss these topics, we are joined by Rene Stephens. Rene leads Renatus Consulting, an independent advisory to CRO and life science clients. His experience spans the outsourced clinical trial procurement process, including procurement and contract negotiation during his time at Pfizer and Astellas, as well as business development during his time at inVentiv Health.

For Disclosures, click here bit.ly/3cPHkNW

https://go.td.com/PodcastDisclosure

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.